Detection of a BMSC-secreted PRL-immunoreactive molecule by Elispot assay. Specific PRL spots in unstimulated BMSC (B) are increased after PAF treatment (C) and the effect is abrogated by the PAF-R antagonist WEB 2170 (D). (A) Elispot of PAF-stimulated BMSC in which the anti-PRL antibody has been omitted.